June 2013

Life sciences

 

Atrium Innovations Announces Distribution Joint Venture in China in Partnership with Fosun Pharma

Atrium Innovations announces that it has entered into a joint venture contract with Fosun Industrial, incorporated in Hong Kong, wholly owned of Shanghai-based Fosun Pharma for the purposes of distributing Atrium brands in China. According to IMS Health Incorporated, Fosun Pharma is one of the top five domestic pharmaceutical companies in the People’s Republic of China by revenue, in the pharmaceutical manufacturing segment. The new joint venture will operate under the FOSIUM Innovations name.

 

Creation of an International Chair on Interventional Cardiology and the Transradial Approach

Creation of an International Chair on Interventional Cardiology and the Transradial Approach

Université Laval rector Denis Brière and vice rector of research and creation Sophie D’Amours announced today the creation of the International Chair on Interventional Cardiology and the Transradial Approach. Attending the event were Andy Williams, Vice President, Global Surgery, Johnson & Johnson Medical Companies, Canada, and Faculty of Medicine professor Dr. Olivier Bertrand, the chairholder.

 

Aeterna Zentaris: First Patient Treated for Phase 2 Trial with AEZS-108 in Triple-Negative Breast Cancer

Aeterna Zentaris announces that a first patient has been treated for the randomized Phase 2 trial in chemotherapy refractory triple-negative luteinizing hormone-releasing hormone receptor-positive metastatic breast cancer, with the Company's targeted doxorubicin peptide conjugate, AEZS 108. 

 

Douglas Laboratories®, business unit of Atrium Innovations, Chosen As the #1 Healthcare Practitioner Brand in ConsumerLab.com Survey

Each year, ConsumerLab.com surveys its free e-newsletter subscribers about the vitamins and supplements they use. Consumers’ answers help guide ConsumerLab.com’s choice of supplements to test and result in a comprehensive 130-page survey report. The survey was fielded in November 2012. Over 10,000 supplement users reported their satisfaction with 1,438 brands and 851 supplement merchants. In the report responses are analyzed by respondent age, gender and level of supplement use.

 

The Canadian Cancer Society grants $2.3 M to three research teams in Quebec

This morning, the Canadian Cancer Society (CCS) announced that it will grant $2.3 million to researchers in Montreal and Quebec City who are aiming to develop cancer vaccines. This includes Dr Yves Fradet’s team at Université Laval aims to apply this approach to bladder cancer. In 2012, this disease affected 7,800 people in Canada and 2,740 people in Quebec. 

 

Asmacure Dosed First Subjects With ASM-024 Dry Powder For Inhalation

Asmacure, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, announced the start of a phase 1/2 clinical trial of its lead compound, ASM-024, in a dry powder for inhalation formulation. The company's lead product, ASM-024, has a novel multi-functional mechanism of action with nicotinic and muscarinic effects and has demonstrated anti-inflammatory effects, bronchoprotection and smooth muscle relaxation in pre-clinical asthma models.

 

Medicago and IDRI Reports Positive Results for its Phase I Clinical Trial for an H5N1 Vaccine

Medicago and IDRI Reports Positive Results for its Phase I Clinical Trial for an H5N1 Vaccine

Medicago and The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, reported positive interim results from a Phase I clinical trial for an H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine"). 

 

Aeterna Zentaris Announces Transfer of Manufacturing Rights Related to Cetrotide® to Merck KGaA

Aeterna Zentaris announced that its German subsidiary has entered into binding agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide® product. The principal effect of such agreements is to transfer manufacturing rights and to grant a manufacturing license for Cetrotide® to a subsidiary of Merck KGaA of Darmstadt, Germany ("Merck Serono"), in all jurisdictions.

 

Medicago successfully produces VLP vaccine candidate for H7N9 virus responsible for recent influenza outbreak in China

Medicago announced that it has successfully produced a new VLP vaccine candidate  for the H7N9 virus that is responsible for the current influenza outbreak in China. "To our knowledge, Medicago is the first to produce a VLP vaccine candidate against this potential pandemic strain demonstrating our  ability to be a first responder in a pandemic scenario," said Andy Sheldon, President and CEO of Medicago.